Rocket Pharmaceuticals (RCKT) Well Positioned Into Life Saving Gene Therapy Catalysts - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT), citing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
